Orchestra BioMed Holdings, Inc. 8-K

What Happened

• On February 12, 2026, Orchestra BioMed Holdings, Inc. (OBIO) filed an 8-K disclosing that its Board, following the Compensation Committee’s recommendation, approved a 2026 cash bonus plan for all executive officers tied to mid-year and full-year performance metrics and stretch goals. The Plan allows payment of up to 25% of annual bonuses in Q3 2026 based on mid‑year measurable metrics, with up to 75% paid in Q1 2027 based on full‑year results (taking into account any mid‑year adjustments).
• The Board also adopted 2026 corporate goals focused on pivotal study enrollment and milestones for the BACKBEAT global pivotal study and the Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) pivotal study, plus financial and operating objectives, and approved difficult-to-achieve 2026 “stretch” goals. Under existing agreements, Messrs. Hochman and Sherman’s 2026 bonuses are 100% tied to these company goals and stretch goals. Mr. Taylor’s bonus is based on company goals plus individual objectives and may be increased by up to 45% or reduced to zero depending on his performance.
• Also on February 12, 2026, the Board approved a revised RSU vesting schedule (25% vesting at 18, 24, 30 and 36 months) and changed compensation for the CEO and President/COO: CEO Michael Hochman’s base pay was increased by 4% and his 2026 target bonus raised from 80% to 100% of base salary; President/COO Adam Sherman’s base pay was increased by 10% and his 2026 target bonus raised from 80% to 90% of base salary.

Key Details

• Date filed: February 12, 2026 (8-K reporting Item 5.02).
• Bonus payout timing: up to 25% paid in Q3 2026 (mid‑year metrics); up to 75% paid in Q1 2027 (full‑year results).
• Executive pay changes: Hochman +4% base; Hochman target bonus 80%→100% of base; Sherman +10% base; Sherman target bonus 80%→90% of base.
• RSU vesting revised to four equal installments: 25% at 18, 24, 30 and 36 months.

Why It Matters

• The changes align senior executive pay with operational milestones—especially enrollment and progress in the BACKBEAT and Virtue SAB pivotal studies—so investors should watch those clinical and partnership updates closely because they directly affect executive payout.
• Mid‑year partial payouts and stretch goals create more near‑term performance incentives and could accelerate management focus on trial enrollment and partnering.
• The salary and target bonus increases slightly raise potential compensation expense, which may modestly affect operating costs; the revised RSU vesting timing affects longer‑term equity dilution and retention dynamics.